Monographie - Tigecycline - Stabilis 4.0

viimane versioon :
14/02/2025

antibiootikum

Tigecycline

Süsteravim

Stabiilsus lahustes

Stabiilsust mõjutavad tegurid

stabiilsust mõjutavad faktorid

Sobimatus

Manustamis viis

Viited

pdf

keemiline struktuur

Kaubanduslikud nimed erinevates maades

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Eticina	Mehhiko
Grexyl	Mehhiko
Linicetil	Mehhiko
Mrsacin	Türgi
Tecygen	Tšiili
Tigecid	Türgi
Tigecilina	Argentiina, Ecuador, Tšiili
Tigecyclin	Saksamaa
Tigecycline	Belgia, Kanada
Tigetop	Tšiili
Tizoxim	Argentiina
Tygacil	Ameerika ühendriigid, Araabia Ühendemiraadid, Argentiina, Austraalia, Austria, Belgia, Ecuador, Hispaania, Holland, Iirimaa, Island, Itaalia, Jaapan, Kanada, Kolumbia, Kreeka, Luksemburg, Malaisia, Maroko, Mehhiko, Norra, Poola, Portugal, Prantsusmaa, Rootsi, Rumeenia, Saksamaa, Saudi Araabia, Soome, Suurbritannia, Sveits, Taani, Tšiili, Türgi, Ungari, uus-Meremaa, Venetsueela
Tyzel	Brasiilia
Zomiprerin	Maroko

Viited

Süsteravim

Viited : Tigecycline

	tüüp	avaldamine
2262	ajaleht	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Labor	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	ajaleht	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Labor	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	Labor	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	Labor	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Labor	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	plakat	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	plakat	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	plakat	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	ajaleht	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	ajaleht	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	ajaleht	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	ajaleht	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	ajaleht	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales